Researchers collaborate on first-in-human study of novel malaria vaccine
An international research collaborative is testing a new approach to malaria vaccine development in humans for the first time. The concept is similar to that used by Edward Jenner to develop a vaccine against smallpox, the only disease affecting humans that has ever been eradicated. Jenner used cowpox, a much less dangerous bovine version of the disease, to inoculate people against smallpox. In this clinical trial, based on data from earlier animal studies conducted by iMM Lisboa, the researchers will use a rodent version of the malaria-causing parasite (Plasmodium berghei) to determine if it can induce protection against infection by Plasmodium falciparum, the deadliest version of the parasite that infects humans.
In the study, a specific gene from P. falciparum known as the circumsporozoite protein (CS), will be inserted into the rodent parasite, resulting in a genetically modified version known as Pb(PfCS@UIS4). By inserting the gene for CS, the researchers hope to improve the potential of the modified rodent parasite to induce a protective response in healthy human volunteers.
"Bringing together the concept underlying the first vaccine ever developed, combined with modern genetic manipulation tools, is a truly innovative approach to malaria vaccination," said Miguel Prudêncio, who is leading the research team at iMM Lisboa.
The trial will be conducted in two phases at Radboudumc in the Netherlands. In the first phase, 18 healthy adult volunteers will be recruited into three groups and exposed to a varying, but carefully controlled number of bites from mosquitoes infected with the genetically modified P. berghei parasite. The researchers will closely monitor volunteers for signs of infection to make sure they are treated if they become ill. If all goes well in the Phase 1 study, volunteers from the highest dose group will enter the second phase of the study, which is designed to assess protective efficacy of the approach.
"This is the first time we have tested a genetically modified malaria vaccine approach in Europe using this rodent parasite," said Robert Sauerwein, principal investigator and professor of medical parasitology at Radboudumc. "Along with our partners in the Netherlands, the Havenziekenhuis and Erasmus MC, we're looking forward to investigating whether this novel concept might one day contribute to the elimination and eradication of this terrible disease."
Malaria killed more than 429,000 people in 2015, most of them young African children. Although the most advanced vaccine in development globally is slated for pilot implementation in parts of Africa beginning in 2018—an incredible accomplishment and critically important step—researchers are still on the hunt for a malaria vaccine that can confer higher levels of durable efficacy. The long-term goal of the malaria vaccine community, as outlined in the World Health Organization's Malaria Vaccine Technology Roadmap, is to develop vaccines with protective efficacy of at least 75 percent against clinical malaria, and vaccines that reduce transmission of the parasite in order to lower the incidence of malaria infection.
"Although much progress has been made to drive down the malaria burden with currently available interventions, a highly effective vaccine would be an important new tool for malaria elimination," said Ashley Birkett, director of PATH's Malaria Vaccine Initiative (MVI). "We are pleased to collaborate with Radboudumc and iMM Lisboa on testing this novel approach."